Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
DHT-UN fair value: what the stock is really worth
As of Oct 2, 2026: fair value of DHT-UN C$13.96, price C$18.40, upside -24.1%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? No
- Add to watchlist
DU
Some data
Sep 24, 2026
DHT-UN
DHT-UN · TOWeak valuationQuality is weak on top of the rich price.
!Fair value C$13.96 · Overvalued (−24.1%)
!Quality 40/100
!Expensive Growth (revenue 3y +34.7 %/yr)
!Loss-making · -25.2% net margin (TTM)
!negative free cash flow
!2.2% dividend yield · Watch coverage
!Narrow moat 34/100
!Evidence only medium, so the estimate is less certain
Watch DHT-UN for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range C$4.37 – C$19.65 · fair‑value band C$13.96 – C$20.00 · the C$18.40 price screens above the C$13.96 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Company profile
DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.
Stock analysis
DHT-UN (DHT-UN) currently trades at C$18.40, while our model-based Fair Value estimate is C$13.96, 24.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of C$25.71 per share, and 2 of the 8 models we run sit above the C$18.40 price.
Bear case: the Dividend Discount group reads lowest at C$6.51, and 6 of the 8 models stay below the price. Evidence for this calculation is medium.
Scenario range: C$13.96 (bear) to C$20.00 (bull), the price of C$18.40 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
DHT-UN reported revenue of $195M in FY2025 versus $73.3M in FY2021, a compound +27.7%/yr. Reported net income was −$51.4M in FY2025.
Key figures
Market cap C$1.1B (≈ $776M) · P/S ratio 5.60 · EPS (TTM) C$−1.28 · Dividend yield 2.2% · Net margin −26.3% · Return on equity −10.4% · Return on assets (EBIT) 6.3% · Operating margin 33.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 6% below its 52-week high and 31% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −24%, DHT-UN screens richer than that median.
Fair Value models
Bear C$13.96
Fair Value C$13.96
Bull C$20.00
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV
C$11.47
C$12.89
C$14.08
70
ROIC Compounder
C$12.62
C$16.45
C$19.64
67
Gordon GGM
C$3.96
C$7.13
C$9.82
65
All 8 models by family
Earnings-Based
EPV
C$11.47
C$12.89
C$14.08
70
Dividend Discount
Gordon GGM
C$3.96
C$7.13
C$9.82
65
DDM Multi-Stage
C$3.96
C$6.51
C$7.62
64
Multiples
EV/EBIT
C$19.53
C$25.71
C$31.89
63
EV/EBITDA
C$42.09
C$55.79
C$69.48
64
EV/Revenue
C$10.72
C$14.89
C$19.05
51
Asset-Based
NCAV (Graham)
C$5.19
C$6.95
C$10.38
51
Economic Profit
ROIC Compounder
C$12.62
C$16.45
C$19.64
67
Notify me when DHT-UN reaches fair value
Put DHT-UN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
40/100
Of which business quality 39 · Market factors (momentum, volatility) 65
Profitability
1
Margins and returns on capital today
Quality Growth
57
Are margins and returns improving?
Cashflow
33
Earnings quality: real cash, not paper profit
Fin. Strength
44
Balance sheet, leverage, solvency risk
Investment
34
Disciplined investing over empire-building
Low Volatility
79
Calm price path (market factor)
Momentum
51
Price trend over the last 3–12 months (market factor)
52W Momentum
71
Distance to the 52-week high (market factor)
Net Issuance
83
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+40.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.7%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
29.4% (2021) → 31.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
DHT-UN screens overvalued: fair value 24% below the price. Compare with Merck KGaA →
Compare DHT-UN with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 569 stocks
Beats the industry median on 6/9 measures
Overall it ranks above its industry peers.
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: Canadian Stocks
- Valuation of the Canada market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €134.45 | €108.94 | −19% |
| Takeda Pharmaceutical Company TAK | $18.90 | $11.45 | −39% |
| Teva Pharmaceutical Industries Limited TEVA | $39.31 | $20.88 | −47% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,852 | ₹1,979 | +7% |
| Galderma Group GALD | CHF 163.00 | CHF 110.32 | −32% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥44.86 | ¥49.35 | +10% |
| Haleon plc HLN | $9.26 | $8.49 | −8% |
| Sandoz Group SDZ | CHF 71.16 | CHF 40.32 | −43% |
| Zoetis Inc ZTS | $70.30 | $110.50 | +57% |
| Divi's Laboratories Limited DIVISLAB | ₹9,620 | ₹1,871 | −81% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is DHT-UN overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of C$13.96 versus a price of C$18.40, about −24% upside (overvalued).
What is the fair value of DHT-UN?
Our model-based fair value for DHT-UN is C$13.96 (as of Sep 24, 2026), built from audited fundamentals. The current price: C$18.40.
What is the quality score of DHT-UN?
DHT-UN has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DHT-UN?
Our model-based price target is the fair value of C$13.96 (as of Sep 24, 2026) from 8 valuation models. Cautious scenario C$13.96, optimistic scenario C$20.00. It is a calculation from audited fundamentals, not an analyst target.
What is the DHT-UN stock forecast for 2026?
Our models put fair value at C$13.96, about −24% upside versus a price of C$18.40 (overvalued). Cautious scenario C$13.96, optimistic scenario C$20.00. The calculation is refreshed regularly with new filings.
What is the revenue of DHT-UN?
DHT-UN reported trailing-twelve-month revenue of about $197M (latest available figure, as of Sep 24, 2026).
Does DHT-UN pay a dividend?
DHT-UN currently shows a dividend yield of about 2.23% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of DHT-UN?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DHT-UN it is C$13.96 per share (as of Sep 24, 2026), against a price of C$18.40. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).
Is DHT-UN stock overvalued or undervalued in 2026?
As of Sep 24, 2026, DHT-UN trades above its calculated fair value: price C$18.40, fair value C$13.96, a gap of about −24% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DHT-UN?
No. The price is what the market pays today (C$18.40); the fair value is what the company's own numbers justify (C$13.96). For DHT-UN the two are C$4.44 per share apart. That gap is exactly why we show both numbers side by side.
How much is DHT-UN worth?
The market values DHT-UN at about C$1.1B (market capitalisation, as of Sep 24, 2026). Per share that is C$18.40; our models calculate a fair value of C$13.96 per share.
What do the bullish and bearish scenarios say about DHT-UN?
Our models span a range for DHT-UN: cautious scenario C$13.96, base C$13.96, optimistic C$20.00 per share (as of Sep 24, 2026, price C$18.40). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of DHT-UN?
Balance-sheet figures for DHT-UN (as of Sep 24, 2026): return on equity −10.4%. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is DHT-UN from its 52-week high?
DHT-UN trades at C$18.40, about 6% below its 52-week high of C$19.65 and 31% above the low of C$14.05 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of C$13.96 is for.
Which stocks are comparable to DHT-UN?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DHT-UN stock attractive at the current price?
The data as of Sep 24, 2026: price C$18.40, calculated fair value C$13.96 (−24%), Quality Score 40/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DHT-UN calculated?
We run DHT-UN through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of C$13.96, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. DHT-UN itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DHT-UN?
The closing price on Oct 2, 2026 was C$18.40. Our model-based fair value is C$13.96, about −24% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DHT-UN right now?
Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of DHT-UN
How large is the market capitalisation of DHT-UN?
The market capitalisation of DHT-UN is C$1.1B (≈ $776M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DHT-UN?
The price-to-sales ratio of DHT-UN is 5.60 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DHT-UN?
Earnings per share at DHT-UN are C$−1.28. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of DHT-UN?
The dividend yield of DHT-UN is 2.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of DHT-UN?
The net margin of DHT-UN is −26.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DHT-UN?
The return on equity (ROE) of DHT-UN is −10.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DHT-UN?
On an EBIT basis the return on assets of DHT-UN is 6.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DHT-UN?
The operating margin of DHT-UN is 33.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DHT-UN?
Revenue at DHT-UN is growing +13.3% versus a year earlier (3y avg +34.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DHT-UN?
Earnings per share at DHT-UN are growing +30.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does DHT-UN generate?
The free cash flow of DHT-UN is −$11.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does DHT-UN carry?
The net debt of DHT-UN is $440M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch DHT-UN in the live analysis
One click puts DHT-UN on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.